RPh Herle - POINT Biopharma Ex Affairs
| PNTDelisted Stock | USD 9.06 0.10 1.09% |
Insider
RPh Herle is Ex Affairs of POINT Biopharma Global
| Phone | 647 812 2417 |
| Web | https://www.pointbiopharma.com |
POINT Biopharma Management Efficiency
The company has Return on Asset of 0.1677 % which means that on every $100 spent on assets, it made $0.1677 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.2633 %, implying that it generated $0.2633 on every 100 dollars invested. POINT Biopharma's management efficiency ratios could be used to measure how well POINT Biopharma manages its routine affairs as well as how well it operates its assets and liabilities.POINT Biopharma Global has 3.56 M in debt with debt to equity (D/E) ratio of 0.01, which may show that the company is not taking advantage of profits from borrowing. POINT Biopharma Global has a current ratio of 10.68, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for POINT to invest in growth at high rates of return.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Adrian Ray | Third Harmonic Bio | 48 | |
| BS CPA | Inhibrx | 42 | |
| Scott Lowe | Oric Pharmaceuticals | N/A | |
| CMA CPA | ESSA Pharma | 65 | |
| Carsten MD | Immatics NV | 57 | |
| Walter Reiher | Revolution Medicines | N/A | |
| Donna Dea | Aerovate Therapeutics | N/A | |
| Annie Lee | Opthea | N/A | |
| Quinn Deveraux | Inhibrx | N/A | |
| Gwen Carscadden | RAPT Therapeutics | 63 | |
| Rodney Young | RAPT Therapeutics | 61 | |
| Adriana MBA | Crinetics Pharmaceuticals | N/A | |
| Jack Anders | Revolution Medicines | 47 | |
| Jeff Knight | Crinetics Pharmaceuticals | 53 | |
| Karen Anderson | Centessa Pharmaceuticals PLC | 56 | |
| Jaume Pons | Alx Oncology Holdings | 58 | |
| Esq JD | Oric Pharmaceuticals | 49 | |
| FESC MD | NewAmsterdam Pharma | 68 | |
| Ian Leitch | Opthea | 61 | |
| Donald MBA | Lyra Therapeutics | 70 | |
| MD MBA | Opthea | N/A | |
Management Performance
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 |
POINT Biopharma Global Leadership Team
Elected by the shareholders, the POINT Biopharma's board of directors comprises two types of representatives: POINT Biopharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of POINT. The board's role is to monitor POINT Biopharma's management team and ensure that shareholders' interests are well served. POINT Biopharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, POINT Biopharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MPH MPH, Ex Devel | ||
| FRCSC MD, Chief Director | ||
| Ari Shomair, VP Staff | ||
| Joe McCann, CEO Director | ||
| Donna BA, VP HR | ||
| RPh Herle, Ex Affairs | ||
| BBA FCA, Chief Officer | ||
| Todd BE, Ex Operations | ||
| Justyna MSc, Chief Officer | ||
| Allan Silber, Ex Chairman | ||
| Dr JD, Sr Devel |
POINT Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is POINT Biopharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.26 | |||
| Return On Asset | 0.17 | |||
| Profit Margin | 0.40 % | |||
| Operating Margin | (10.62) % | |||
| Current Valuation | 1 B | |||
| Shares Outstanding | 106.57 M | |||
| Shares Owned By Insiders | 14.97 % | |||
| Shares Owned By Institutions | 48.91 % | |||
| Number Of Shares Shorted | 2.64 M | |||
| Price To Book | 3.13 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Other Consideration for investing in POINT Stock
If you are still planning to invest in POINT Biopharma Global check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the POINT Biopharma's history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |